The duration of treatment should be at least 1 year. Since different patients have different treatment responses, the course of treatment cannot be exactly the same, and the individualization and long-term nature of the course of treatment should be emphasized, which can be referred to as follows. 1, HBeAg-positive patients before treatment, the comprehensive efficacy of the treatment at 1 year completely respond recommended to continue the drug for at least another 6 months, interval of 3 months to review once, still maintain a complete response can be discontinued for observation. 2, HBeAg-positive patients before treatment, those with partial response at 1 year of treatment are recommended to continue medication until complete response is achieved, then continue medication for at least 6 months, with 3 months interval for review, and those who still maintain complete response can stop medication for observation. 3, HBeAg-negative chronic hepatitis B patients with active HBV DNA replication, comprehensive treatment for at least 2 years for complete response. 4, regardless of HBeAg positive or negative patients before treatment, the comprehensive efficacy at 1 year of treatment still does not respond to the drug can be discontinued for observation, or change to other effective antiviral drug treatment. For patients with cirrhosis or combined hepatic decompensation whose clinical manifestations or other indicators such as liver biopsy show progression, the drug should not be discontinued easily and symptomatic liver-protective treatment should be strengthened.